The Development of Live Biotherapeutics Against Infection Towards Reconstituting Gut Microbiota

Overview

Journal Gut Microbes

Specialties Gastroenterology
Microbiology

Date 2022 Mar 23

PMID 35319337

Authors

Yongrong Zhang

Ashley Saint Fleur

Hanping Feng

Affiliations

Soon will be listed here.

Abstract

is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field.

Citing Articles

The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.

Berry P, Khanna S Indian J Gastroenterol. 2025; .

PMID: 39821715 DOI: 10.1007/s12664-024-01717-9.

Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.

Raeisi H, Leeflang J, Hasan S, Woods S Probiotics Antimicrob Proteins. 2024; .

PMID: 39531149 DOI: 10.1007/s12602-024-10398-x.

Symbiotic biofilms formed by and in the presence of vancomycin.

Yang J, Rui W, Zhong S, Li X, Liu W, Meng L Gut Microbes. 2024; 16(1):2390133.

PMID: 39132815 PMC: 11321409. DOI: 10.1080/19490976.2024.2390133.

Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet.

Montgomery T, Peipert D, Krementsov D Immunol Rev. 2024; 325(1):131-151.

PMID: 38717158 PMC: 11338732. DOI: 10.1111/imr.13343.

Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following challenge.

Wan S, You P, Shi Q, Hu H, Zhang L, Chen L Front Microbiol. 2024; 15:1368194.

PMID: 38638911 PMC: 11024471. DOI: 10.3389/fmicb.2024.1368194.

References

Vedantam G, Kochanowsky J, Lindsey J, Mallozzi M, Roxas J, Adamson C . An Engineered Synthetic Biologic Protects Against Infection. Front Microbiol. 2018; 9:2080. PMC: 6134020. DOI: 10.3389/fmicb.2018.02080. View

Crobach M, Vernon J, Loo V, Kong L, Pechine S, Wilcox M . Understanding Clostridium difficile Colonization. Clin Microbiol Rev. 2018; 31(2). PMC: 5967689. DOI: 10.1128/CMR.00021-17. View

Rea M, OSullivan O, Shanahan F, OToole P, Stanton C, Ross R . Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol. 2011; 50(3):867-75. PMC: 3295116. DOI: 10.1128/JCM.05176-11. View

Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E . Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003; 41(11):5340-3. PMC: 262466. DOI: 10.1128/JCM.41.11.5340-5343.2003. View

Elahi M, Nakayama-Imaohji H, Hashimoto M, Tada A, Yamasaki H, Nagao T . The Human Gut Microbe Suppresses Toxin Release from by Inhibiting Autolysis. Antibiotics (Basel). 2021; 10(2). PMC: 7918992. DOI: 10.3390/antibiotics10020187. View

McDonald J, Mullish B, Pechlivanis A, Liu Z, Brignardello J, Kao D . Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota. Gastroenterology. 2018; 155(5):1495-1507.e15. PMC: 6347096. DOI: 10.1053/j.gastro.2018.07.014. View

Meader E, Mayer M, Steverding D, Carding S, Narbad A . Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe. 2013; 22:25-30. DOI: 10.1016/j.anaerobe.2013.05.001. View

Szajewska H, Kolodziej M . Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015; 42(7):793-801. DOI: 10.1111/apt.13344. View

Wong S, Jamous A, ODriscoll J, Sekhar R, Weldon M, Yau C . A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr. 2013; 111(4):672-8. DOI: 10.1017/S0007114513002973. View

10.

Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli G, Mancabelli L . Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep. 2016; 6:25945. PMC: 4863157. DOI: 10.1038/srep25945. View

11.

Youngster I, Russell G, Pindar C, Ziv-Baran T, Sauk J, Hohmann E . Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014; 312(17):1772-8. DOI: 10.1001/jama.2014.13875. View

12.

Rea M, Sit C, Clayton E, OConnor P, Whittal R, Zheng J . Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A. 2010; 107(20):9352-7. PMC: 2889069. DOI: 10.1073/pnas.0913554107. View

13.

Verdier C, Denis S, Gasc C, Boucinha L, Uriot O, Delmas D . An Oral FMT Capsule as Efficient as an Enema for Microbiota Reconstruction Following Disruption by Antibiotics, as Assessed in an In Vitro Human Gut Model. Microorganisms. 2021; 9(2). PMC: 7918368. DOI: 10.3390/microorganisms9020358. View

14.

Amrane S, Hocquart M, Afouda P, Kuete E, Pham T, Dione N . Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection. Sci Rep. 2019; 9(1):12807. PMC: 6728329. DOI: 10.1038/s41598-019-49189-8. View

15.

Lawson P, Citron D, Tyrrell K, Finegold S . Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016; 40:95-9. DOI: 10.1016/j.anaerobe.2016.06.008. View

16.

Youngster I, Sauk J, Pindar C, Wilson R, Kaplan J, Smith M . Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014; 58(11):1515-22. PMC: 4017893. DOI: 10.1093/cid/ciu135. View

17.

Hernandez M, de Frutos M, Rodriguez-Lazaro D, Lopez-Urrutia L, Quijada N, Eiros J . Fecal Microbiota of Toxigenic -Associated Diarrhea. Front Microbiol. 2019; 9:3331. PMC: 6341279. DOI: 10.3389/fmicb.2018.03331. View

18.

Liu C, Chang J, Chang Y, Mou K . Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide. J Mol Med (Berl). 2020; 98(12):1675-1687. DOI: 10.1007/s00109-020-01987-8. View

19.

McGovern B, Ford C, Henn M, Pardi D, Khanna S, Hohmann E . SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis. 2020; 72(12):2132-2140. PMC: 8204772. DOI: 10.1093/cid/ciaa387. View

20.

Maltz C, Miskovitz P, Hajifathalian K . Lactulose may reduce -related diarrhea among patients receiving antibiotics. JGH Open. 2020; 4(6):1088-1090. PMC: 7731830. DOI: 10.1002/jgh3.12390. View